Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. - Test2 - elhamkhani - TriplyDB

Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.

Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.

http://www.wikidata.org/entity/Q37203951

about

Blood cells: an historical account of the roles of purinergic signalling Role of prostacyclin in pulmonary hypertension.Platelet function tests: why they fail to guide personalized antithrombotic medication Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1.Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.Structure, Pharmacology and Roles in Physiology of the P2Y12 Receptor.Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.Reversal of stress fibre formation by Nitric Oxide mediated RhoA inhibition leads to reduction in the height of preformed thrombi.The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy.

P2860

Q26799623-8414C74A-1E72-4E09-B290-756AA307C7A1 Q35165100-4A2F068D-4498-43BD-81E3-B3B0A54E50B8 Q36141482-04631692-3990-4F3F-8381-34B3A7B2EE11 Q36622844-47A04229-66FF-48EB-AD39-87B9E93DF358 Q37403729-7C183225-76EF-43FD-8865-74A4EEE7B659 Q38694069-73E91683-70C4-40F5-B2E6-0E88FC1F1588 Q39221284-B450387A-0226-41BB-8783-25DB28A96BB3 Q41060485-DE5A6EBD-0CD3-47A8-BB8D-C7E1FA3CFA71 Q47786748-43AEE41F-62D7-4234-A256-0E4255DBF7DE Q48265369-B6856387-7A8F-4722-953F-66629C580760 Q50324626-8258AB96-B934-485F-AFE3-DE910F0C98D0 Q53191924-261A6B96-5BAF-4D4C-8044-F65C87767E39

P2860

Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.

http://www.wikidata.org/entity/Q37203951

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Blockade of the purinergic P2Y ...... itory actions of nitric oxide.

@en

Blockade of the purinergic P2Y ...... itory actions of nitric oxide.

@nl

type

label

Blockade of the purinergic P2Y ...... itory actions of nitric oxide.

@en

Blockade of the purinergic P2Y ...... itory actions of nitric oxide.

@nl

prefLabel

Blockade of the purinergic P2Y ...... itory actions of nitric oxide.

@en

Blockade of the purinergic P2Y ...... itory actions of nitric oxide.

@nl

P1433

Q37203951-1121D514-FB09-4573-9613-691BFECB441C

P1476

Q37203951-BE789F48-3D75-481E-A148-93885D0BF286

P2093

Q37203951-4930F9F6-84CC-4A99-9CF1-1E3BC32C647E

Q37203951-63397E1F-DA7E-4A94-BBBA-060B38BF4F6D

Q37203951-841654C7-B4E8-470A-8A6F-B713BA847587

Q37203951-EDD80A32-D696-448F-8273-DBE0B6D9E1BA

P2860

Q37203951-08730C89-E593-426C-9C30-05A08755D599

Q37203951-22B4296C-8083-4C7A-8E87-A6558CE8B7D7

Q37203951-2C2B4B3C-D7F1-457F-832C-49B73EE72BF8

Q37203951-46B42D69-898B-4A0D-BCB5-BFFEA0F4A639

Q37203951-490410FC-EF38-46F1-BEAE-0EB42ECB4AEF

Q37203951-56F84FA1-168E-407F-8DB2-A5BA02DBF7D6

Q37203951-5DB8E3AA-38A9-4085-AFAC-C7CE67E67F05

Q37203951-5E3BA9ED-03B1-47D2-B777-D135ED78CC6D

Q37203951-7AA82C22-69F7-4C1D-BC63-98D3B7E56EFC

Q37203951-86634969-155F-441C-8EB3-E4DC6F2E05C0

P304

Q37203951-8B329C09-922C-4ED7-BC8D-2E844B03B14B

P31

Q37203951-DBAEEFEF-F1AF-4A8D-A37A-4101BA7DFCD5

P356

Q37203951-C4D9C9A3-FC4E-4380-BE30-FEC8F2E207ED

P407

Q37203951-19BF91E7-8A8C-4221-A728-0552E242817D

P433

Q37203951-465D25A1-3624-4C7F-8146-99B45D7F09FC

P478

Q37203951-DD373793-A9AC-4FE7-8D3F-53EFB9551692

P50

Q37203951-13D279A0-052E-4F11-B599-0041931FE4BF

Q37203951-53359F9E-0861-41FE-9299-CBAF426B1085

Q37203951-9C82A12B-28A6-4DD6-9726-6C5F79C5E61E

Q37203951-EA087615-4F9F-4C5F-9A8B-98AADC3DF7EB

P577

Q37203951-50A338EB-FB64-44E4-88E1-401262023D84

P5875

Q37203951-E7F84C4F-E207-4E8B-960F-D0B90C37FB56

P698

Q37203951-ED5B44D3-A986-45FE-BF4C-1FD5980463C0

P932

Q37203951-0DF2FFBB-54F2-452D-AD83-AD76E5FCD782

P356

PNAS.1218880110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Blockade of the purinergic P2Y ...... itory actions of nitric oxide.

@en

P2093

Antonia B Solomon

http://www.w3.org/2001/XMLSchema#string

Ivana Vojnovic

http://www.w3.org/2001/XMLSchema#string

Jane A Mitchell

http://www.w3.org/2001/XMLSchema#string

Michael Emerson

http://www.w3.org/2001/XMLSchema#string

P2860

IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation

KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells

ADP secretion and subsequent P2Y12 receptor signalling play a crucial role in thrombin-induced ERK2 activation in human platelets

Endogenous nitric oxide and prostaglandins synergistically counteract thromboembolism in arterioles but not in venules

Clinical aspects of platelet inhibitors and thrombus formation

Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model

cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets

Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor.

An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.

The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function.

P304

15782-15787

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1218880110

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Martina H Lundberg

Timothy D Warner

Nicholas S Kirkby

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256425881

http://www.w3.org/2001/XMLSchema#string

P698

24003163

http://www.w3.org/2001/XMLSchema#string

P932

3785756

http://www.w3.org/2001/XMLSchema#string